MarketCap
Facebook
X
Telegram
Agilent Technologies EBITDA | A
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Agilent Technologies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.77 B | 1.74 B | 1.62 B | 1.94 B | 1.67 B | 1.15 B | 1.18 B | 1.14 B | 1.05 B | 861 M | 775 M | 1.22 B | 1.32 B | 1.42 B | 1.32 B | 768 M | 209 M | 996 M | 775 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.94 B | 209 M | 1.21 B |
Quarterly EBITDA Agilent Technologies
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 533 M | 420 M | 420 M | - | 386 M | 448 M | 448 M | - | 358 M | 446 M | 446 M | 342 M | 521 M | 421 M | 458 M | - | - | 411 M | 404 M | - | 489 M | 333 M | 294 M | 779 M | 385 M | 149 M | 304 M | 853 M | 332 M | 242 M | 280 M | 814 M | 322 M | 236 M | 261 M | 768 M | 310 M | 233 M | 221 M | 622 M | 276 M | 171 M | 183 M | 559 M | 275 M | 145 M | 220 M | 640 M | 324 M | 143 M | 311 M | 943 M | 422 M | 263 M | 333 M | 1.05 B | 393 M | 326 M | 274 M | 948 M | 408 M | 297 M | 250 M | 229 M | 133 M | 121 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.05 B | 121 M | 399 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Diagnostics research industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Fulgent Genetics
FLGT
|
-67 M | $ 23.68 | 26.9 % | $ 729 M |  USA |
 |
CareDx, Inc
CDNA
|
-15.8 M | $ 78.47 | 2.8 % | $ 4.18 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-3.26 M | - | - | $ 562 M |  Britain |
 |
Biomerica
BMRA
|
-5.24 M | $ 1.61 | -1.55 % | $ 4.69 M | USA |
 |
Interpace Biosciences
IDXG
|
4.51 M | $ 7.0 | -13.43 % | $ 31 M | USA |
 |
Fluidigm Corporation
FLDM
|
-35.1 M | - | 1.08 % | $ 308 M | USA |
 |
ICON Public Limited Company
ICLR
|
826 M | $ 204.67 | 1.5 % | $ 16.1 B |  Irlanda |
 |
Co-Diagnostics
CODX
|
-49.1 M | $ 0.25 | -8.24 % | $ 333 K | USA |
 |
Burning Rock Biotech Limited
BNR
|
-33.1 M | $ 13.2 | -0.38 % | $ 139 M |  China |
 |
PRA Health Sciences, Inc.
PRAH
|
416 M | - | - | $ 10.7 B | USA |
 |
DarioHealth Corp.
DRIO
|
-36.3 M | $ 2.4 | -11.93 % | $ 9.56 M |  Israel |
 |
Myriad Genetics
MYGN
|
-334 M | $ 5.97 | -5.17 % | $ 553 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-5.72 M | $ 4.73 | -5.49 % | $ 3.72 M | USA |
 |
NeoGenomics
NEO
|
-79.8 M | $ 16.85 | 2.18 % | $ 2.16 B | USA |
 |
OPKO Health
OPK
|
-25.8 M | $ 1.72 | -1.71 % | $ 1.29 B | USA |
 |
Pacific Biosciences of California
PACB
|
-541 M | $ 2.3 | -5.35 % | $ 690 M | USA |
 |
Neogen Corporation
NEOG
|
94.7 M | $ 11.75 | 0.6 % | $ 2.56 B | USA |
 |
Precipio
PRPO
|
43 K | $ 18.95 | 2.02 % | $ 30.4 M | USA |
 |
Personalis
PSNL
|
-78 M | $ 15.76 | 1.32 % | $ 1.41 B | USA |
 |
Sotera Health Company
SHC
|
94.9 M | $ 16.01 | 0.88 % | $ 4.55 B | USA |
 |
Quidel Corporation
QDEL
|
1.11 B | $ 10.69 | -16.78 % | $ 450 M | USA |
 |
Centogene N.V.
CNTG
|
-29.7 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Global Cord Blood Corporation
CO
|
652 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
-6 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-702 M | - | 0.12 % | $ 80.1 M | China |
 |
Aspira Women's Health
AWH
|
-7.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-2.37 M | - | - | $ 9.42 M | Israel |
 |
Exact Sciences Corporation
EXAS
|
-81.4 M | - | - | $ 19.8 B | USA |
 |
National Research Corporation
NRC
|
30.2 M | $ 25.62 | 0.55 % | $ 573 M | USA |
 |
Twist Bioscience Corporation
TWST
|
-111 M | $ 120.83 | 0.18 % | $ 7.23 B | USA |
 |
Organovo Holdings
ONVO
|
-11.3 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
24.2 M | - | -16.95 % | $ 1.54 M | USA |
 |
PerkinElmer
PKI
|
762 M | - | -0.91 % | $ 14.7 B | USA |
 |
Soleno Therapeutics
SLNO
|
11.4 M | - | - | $ 2.69 B | USA |
 |
Enzo Biochem
ENZ
|
-11.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Quest Diagnostics Incorporated
DGX
|
2.13 B | $ 257.93 | 1.18 % | $ 28.6 B | USA |
 |
Danaher Corporation
DHR
|
5.44 B | $ 230.45 | 1.76 % | $ 164 B | USA |
 |
IDEXX Laboratories
IDXX
|
1.51 B | $ 676.3 | 0.83 % | $ 54.4 B | USA |
 |
Illumina
ILMN
|
1.08 B | $ 213.05 | 2.43 % | $ 33 B | USA |
 |
Lantheus Holdings
LNTH
|
381 M | $ 100.61 | -0.09 % | $ 6.79 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-33.9 M | - | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
562 M | $ 653.24 | 2.88 % | $ 18.8 B | USA |
 |
Mettler-Toledo International
MTD
|
51.1 M | $ 1 722.36 | 2.64 % | $ 35.5 B |  Schweiz |
 |
Natera
NTRA
|
-268 M | $ 319.38 | -12.2 % | $ 43.7 B | USA |
 |
Charles River Laboratories International
CRL
|
428 M | $ 338.13 | 8.07 % | $ 16.8 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
2.55 B | $ 30.33 | -0.57 % | $ 28.8 B |  Niderland |
 |
QIAGEN N.V.
QGEN
|
660 M | $ 50.36 | -0.98 % | $ 10.9 B | Niderland |
 |
RadNet
RDNT
|
214 M | $ 75.83 | -2.79 % | $ 5.7 B | USA |
 |
Senseonics Holdings
SENS
|
-66.8 M | $ 8.58 | 7.38 % | $ 358 M | USA |
 |
T2 Biosystems
TTOO
|
-48.8 M | - | -39.35 % | $ 313 K | USA |